Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
- Company to terminate the ADAPT study — - Company has retained Stifel to provide advice on possible strategic alternatives — - Trading in the common stock to be transferred from Nasdaq to the OTCQB Venture Market - DURHAM, N.C., April 19, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc.
View HTML
Toggle Summary Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today reported financial results
View HTML
Toggle Summary Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it will
View HTML
Toggle Summary Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
Patent Related to Strain-Independent Amplification of HIV Nucleic Acid Sequences
View HTML
Toggle Summary Argos Obtains Option to License PD1 Checkpoint Inhibitors
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb.
View HTML
Toggle Summary Argos Announces One-for-Twenty Reverse Stock Split
- Nasdaq Panel Determines to Allow Continued Listing on The Nasdaq Capital Market Subject to Certain Conditions -
View HTML
Toggle Summary Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.
DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has signed
View HTML
Toggle Summary Argos Provides Financial Update
DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that TKC
View HTML
Toggle Summary Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
DURHAM, N.C., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today provided an update on the
View HTML
Toggle Summary Argos Reports Third Quarter 2017 Financial Results and Operational Highlights
DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today reported financial results
View HTML

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Tweets